OCGNFrom entry, took longer then excpected but the jump finally came. 100% gain from the 2.71 call entry.
OCGN trade ideas
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market.
Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market.
Ocugen and Bharat Biotech to share US commercialization profits.
Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US.
COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients.
COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape.
today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market.
Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market .
B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits.
In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program.
H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market.
Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements.
Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday.
Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
$OCGNBull flag
4hr and daily hidden bullish divergence on the RSI and MACD
Stop = Under candle wick of last touch of support
1st Target = High of previous rally
2nd Target = 1.618 fib extension
OCGN could have another runAccording to Elliot Wave Thoery, we could see a another potential run on OCGN.
$OCGN PT 6-12 and higherOcugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
either big upside or downside I bought this after hours for $1.94 for 38 shares. bounced off the VWAP and can break through the top resistance. if it does we will see big upside. if not well i loose my money. good luck happy trading don't do it like that
oh boy I just bought this after hours in hopes of the triangle breaking. don't invest like this kids
OCGN LONGThis could be an incredible payout, now only time will tell, stock shows institutional interest, with a confirmed breakout.
$OCGN Ocugen Inc Not Finished yet
On the top of the watchlist for parabolic moves
Today. Already up on heavy volume after yesterdays 170% move.
Volume Resistance is very low above $2.00 and almost non
existence above $2.73
Keep on alert for possible trade above $1.64
$OCGN is gonna fall todayPupm&Dump trading strategy idea.
$OCGN is rising without clear preconditions today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $0,449;
stop-loss — $0,512;
take-profit — $0,323;
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Fourth FDA Orphan Drug Designation for OCU400 (AAV-NR2E3)Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases
The FDA Office of Orphan Products Development grants orphan designation for novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the U.S. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including a seven-year period of U.S. marketing exclusivity, tax credits for clinical research costs, clinical research trial design assistance, the ability to apply for annual grant funding and waiver of Prescription Drug User Fee Act filing fees.
finance.yahoo.com
Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease
Third orphan drug designation for the same product
finance.yahoo.com
TWITTER
It seems they received a Notice of Allowance for ANOTHER U.S. patent and just paid their fee last week. I assume we will hear about this too in addition to their latest orphan drug status designation? They have a lot of good news. A bit of insider purchases in May too.
I assume they will announce both soon. Typically no pr is made until the notice of issue is granted with the patent number & grant date. This happens shortly after the notice of allowance is granted and the fee is received (& other minor administrative items are completed).
It has not even started clinical trials yet! Face with tears of joy Lol!! orphan drug status means the costs to test and develop will be substantially subsidized by the government for public policy reasons. So this is basically an announcement that they received a free $150M.
According to the FDA website, $OCGN just received orphan drug status to complete its OCU400 modifier gene therapy platform! I have not seen any PR yet. They will also present at the World Orphan Drug Congress next month.
OCUGEN MAJOR BULL RUN INCOMING!Hey guys!
A lot of you may not know this but I actually do some stock trading on the side as well as creating YouTube videos.
Recently I came across this stock and honestly in my past 5 years of trading I have never come across something that looks more of an attractive buy than this stock...OCUGEN!
And I'm going to explain why for a number of reasons.
1) We can see a clear elliot wave 1 & 2 being completed with a 0.618 retracement on the fibonacci
2) As the retracement was heavy for wave 2, we can expect the retracement for wave 4 to be less and indeed we do see this as wave 3 hits a peak and wave 4 retraces to the 0.382
3) Wave 5 is sure to be a fruitful wave! Take a look at everything from the RSI showing an amazing trend line on the 30 minute & histogram now ticking to the positive on the hourly
4) Lastly...switch over to monthly. THERE HASN'T BEEN VOLUME LIKE THIS IN MONTHS!
Definitely bullish and I'll be keeping an eye out for a breakout past the triangle.
Happy trading!
